Adma Biologics Inc Dossier
Qualitative Analysis
Business overview
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics. The company targets immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its primary FDA-approved commercial products include ASCENIV and BIVIGAM (immune globulin intravenous products), as well as Nabi-HB (for hepatitis B). ADMA operates its own FDA-licensed plasma collection centers and a state-of-the-art fractionation and purification facility in Boca Raton, Florida.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the patented yield-enhanced manufacturing process into its first full year of routine commercial operation in 2026.
Expected impact: Substantial gross margin expansion and increased earnings power by maximizing output per plasma batch.
Implementing a $200 million capital return initiative in 2026, highlighted by a $125 million Accelerated Share Repurchase (ASR) agreement with JPMorgan Chase.
Expected impact: Enhancement of long-term stockholder value and optimization of capital structure.
Deploying the proprietary ADMAlytics AI program to optimize supply chain, production, and commercial planning.
Expected impact: Improved operational efficiencies, better inventory management, and enhanced commercial execution.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of real estate in Boca Raton, FL, to expand production operations and provide storage redundancies.
Financial impact: Increases capital assets and provides long-term operational security for manufacturing.
Strategic Partnerships
Replaced the previous Ares Credit Agreement with a new $300 million senior secured credit facility (including a $75 million term loan and a $225 million revolving credit facility).
Terms: $300 million total capacity, improving financial flexibility and lowering cost of capital.
Expands the commercial distribution network for ASCENIV and BIVIGAM to open new sites of care and reach broader patient populations.
Terms: Standard commercial distribution terms.
Divested three FDA-licensed plasma collection centers for $12 million while securing long-term supply agreements to maintain access to high-titer plasma.
Terms: $12 million in cash proceeds, generating an approximate $8 million gain, while reducing operating complexity.